Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 17, Issue 1, Pages 49-64Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41571-019-0272-7
Keywords
-
Categories
Funding
- BMS
- Fondation MSD Avenir
- INSERM [CIC 1428]
- Institut National du Cancer (INCa)
- SIRIC Stratified Oncology Cell DNA Repair and Tumour Immune Elimination (SOCRATE)
- Agence National de la Recherche (ANR) -Projets blancs
- ANR
- ERA-Net for Research on Rare Diseases
- Association pour la recherche sur le cancer (ARC)
- Canceropole Ile-de-France
- Chancellerie des universites de Paris (Legs Poix)
- Elior
- European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR)
- European Union Horizon 2020 Project Oncobiome
- Fondation Carrefour
- High-end Foreign Expert Program in China [GDW20171100085, GDW20181100051]
- Fondation pour la Recherche Medicale (FRM)
- Gustave Roussy Odyssea, Inserm (HTE)
- Institut Universitaire de France
- LabEx Immuno-Oncology
- LeDucq Foundation
- Ligue contre le Cancer (equipe labellisee)
- RHU Torino Lumiere
- Seerave Foundation
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
Ask authors/readers for more resources
Local administration of oncolytic viruses to tumours can promote anticancer immune responses that lead to the abscopal regression of distant metastases, especially in patients receiving systemic immune-checkpoint inhibitors. Growing preclinical evidence indicates that non-virally induced oncolysis, defined as chemical or physical treatment administered locally to destroy malignant lesions, can promote a similar effect owing to the release of danger-associated molecular patterns that lead to the recruitment of immune cells, thus inducing a systemic response against tumour antigens that protects against local disease relapse and also mediates distant antineoplastic effects. An accumulating body of preclinical evidence supports the implementation of therapies that combine oncolysis with local or systemic immunotherapies. In this Review, we summarize the available data on innovative non-viral oncolysis strategies, including intratumorally applied cytotoxicants, photodynamic therapy, laser therapy, microwave, radiofrequency or photothermal ablation, high-intensity focused ultrasonography and cryotherapy for the local treatment of patients with solid tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available